AstraZeneca Pharma India Limited
AstraZeneca Pharma India received permission to import, sell, and distribute Acalabrutinib tablets (Calquence®) for an additional indication in India. This approval targets previously untreated chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL), to be used in combination with venetoclax with or without obinutuzumab.
Apr 10 2026 17:04:00
AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited is conducting a postal ballot for shareholder approval to shift its registered office from Karnataka to Maharashtra. This move aims to enhance administrative and operational efficiency for the company.
Apr 10 2026 17:04:00
AstraZeneca Pharma India Ltd - 506820 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
AstraZeneca Pharma proposes a special resolution via postal ballot to relocate its registered office from Karnataka to Maharashtra. This strategic move aims to improve operational efficiency and strengthen its presence in Mumbai, with e-voting from April 12, 2026, to May 11, 2026.
Apr 10 2026 17:04:00
AstraZeneca Pharma India Limited
AstraZeneca Pharma India appointed Dr. Shashank Srinivasan as Medical Director - Oncology Business Unit and Mr. Venkat Natarajan as Director - Market Access Business Unit. These key management personnel appointments are effective from April 1, 2026, strengthening the leadership team in critical areas.
Mar 31 2026 19:03:00
AstraZeneca Pharma India Limited
AstraZeneca Pharma India's postal ballot results confirm shareholder approval of material related party transactions with AstraZeneca UK Limited and AstraZeneca AB, Sweden. The resolutions passed with a significant majority of votes from non-related members, ensuring the company can proceed with these essential business dealings.
Mar 31 2026 16:03:00
Read More